[go: up one dir, main page]

WO2000068384A3 - NOVEL NUCLEIC ACIDS AND PROTEINS WITH p53 ACTIVITY AND ALTERED TETRAMERIZATION DOMAINS - Google Patents

NOVEL NUCLEIC ACIDS AND PROTEINS WITH p53 ACTIVITY AND ALTERED TETRAMERIZATION DOMAINS Download PDF

Info

Publication number
WO2000068384A3
WO2000068384A3 PCT/US2000/013248 US0013248W WO0068384A3 WO 2000068384 A3 WO2000068384 A3 WO 2000068384A3 US 0013248 W US0013248 W US 0013248W WO 0068384 A3 WO0068384 A3 WO 0068384A3
Authority
WO
WIPO (PCT)
Prior art keywords
proteins
nucleic acids
activity
novel nucleic
tetramerization domains
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2000/013248
Other languages
French (fr)
Other versions
WO2000068384A2 (en
Inventor
Klaus Fiebig
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xencor Inc
Original Assignee
Xencor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xencor Inc filed Critical Xencor Inc
Priority to EP00930723A priority Critical patent/EP1179062A2/en
Priority to JP2000616350A priority patent/JP2003520023A/en
Priority to AU48492/00A priority patent/AU4849200A/en
Priority to CA002372881A priority patent/CA2372881A1/en
Publication of WO2000068384A2 publication Critical patent/WO2000068384A2/en
Publication of WO2000068384A3 publication Critical patent/WO2000068384A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The invention relates to novel p53 proteins with altered tetramerization domains (tet-p53) proteins and nucleic acids. The invention further relates to the use of the tet-p53 proteins in the treatment of p53 related disorders.
PCT/US2000/013248 1999-05-12 2000-05-12 NOVEL NUCLEIC ACIDS AND PROTEINS WITH p53 ACTIVITY AND ALTERED TETRAMERIZATION DOMAINS Ceased WO2000068384A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP00930723A EP1179062A2 (en) 1999-05-12 2000-05-12 Nucleic acids and proteins with p53 activity and altered tetramerization domains
JP2000616350A JP2003520023A (en) 1999-05-12 2000-05-12 Novel nucleic acids and proteins with p53 activity and altered tetramerization domains
AU48492/00A AU4849200A (en) 1999-05-12 2000-05-12 Novel nucleic acids and proteins with p53 activity and altered tetramerization domains
CA002372881A CA2372881A1 (en) 1999-05-12 2000-05-12 Novel nucleic acids and proteins with p53 activity and altered tetramerization domains

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13378399P 1999-05-12 1999-05-12
US60/133,783 1999-05-12

Publications (2)

Publication Number Publication Date
WO2000068384A2 WO2000068384A2 (en) 2000-11-16
WO2000068384A3 true WO2000068384A3 (en) 2001-02-15

Family

ID=22460283

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/013248 Ceased WO2000068384A2 (en) 1999-05-12 2000-05-12 NOVEL NUCLEIC ACIDS AND PROTEINS WITH p53 ACTIVITY AND ALTERED TETRAMERIZATION DOMAINS

Country Status (5)

Country Link
EP (1) EP1179062A2 (en)
JP (1) JP2003520023A (en)
AU (1) AU4849200A (en)
CA (1) CA2372881A1 (en)
WO (1) WO2000068384A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001009325A2 (en) * 1999-07-30 2001-02-08 The Government Of The United States Of America, Asrepresented By The Secretary, Dept. Of Health And Human Services Human p53 mutations and a genetic system in yeast for functional indentification of human p53 mutations
US7256260B1 (en) 1999-07-30 2007-08-14 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services, Nih Human p53 mutations and a genetic system in yeast for functional identification of human p53 mutations
WO2003045415A2 (en) * 2001-11-26 2003-06-05 University Health Network Self-assembling p53 peptides as gene delivery vehicles

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996016989A1 (en) * 1994-11-28 1996-06-06 The Wistar Institute Of Anatomy And Biology p53 PROTEINS WITH ALTERED TETRAMERIZATION DOMAINS
WO1998031703A1 (en) * 1997-01-17 1998-07-23 The Wistar Institute Of Anatomy & Biology Methods for altering three-dimensional protein structure and compositions produced thereby
WO2000022115A2 (en) * 1998-10-13 2000-04-20 Board Of Regents, The University Of Texas System Assays for identifying functional alterations in the p53 tumor suppressor

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996016989A1 (en) * 1994-11-28 1996-06-06 The Wistar Institute Of Anatomy And Biology p53 PROTEINS WITH ALTERED TETRAMERIZATION DOMAINS
WO1998031703A1 (en) * 1997-01-17 1998-07-23 The Wistar Institute Of Anatomy & Biology Methods for altering three-dimensional protein structure and compositions produced thereby
WO2000022115A2 (en) * 1998-10-13 2000-04-20 Board Of Regents, The University Of Texas System Assays for identifying functional alterations in the p53 tumor suppressor

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
MATEU MAURICIO G ET AL: "Mutually compensatory mutations during evolution of the tetramerization domain of tumor suppressor p53 lead to impaired hetero-oligomerization.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 96, no. 7, 30 March 1999 (1999-03-30), March 30, 1999, pages 3595 - 3599, XP002152303, ISSN: 0027-8424 *
MATEU MAURICIO G ET AL: "Nine hydrophobic side chains are key determinants of the thermodynamic stability and oligomerization status of tumour suppressor p53 tetramerization domain.", EMBO (EUROPEAN MOLECULAR BIOLOGY ORGANIZATION) JOURNAL, vol. 17, no. 10, 15 May 1998 (1998-05-15), pages 2748 - 2758, XP002152304, ISSN: 0261-4189 *
STAVRIDI ELENA S ET AL: "Change in oligomerization specificity of the p53 tetramerization domain by hydrophobic amino acid substitutions.", PROTEIN SCIENCE, vol. 8, no. 9, September 1999 (1999-09-01), pages 1773 - 1779, XP002152305, ISSN: 0961-8368 *

Also Published As

Publication number Publication date
EP1179062A2 (en) 2002-02-13
WO2000068384A2 (en) 2000-11-16
JP2003520023A (en) 2003-07-02
CA2372881A1 (en) 2000-11-16
AU4849200A (en) 2000-11-21

Similar Documents

Publication Publication Date Title
WO2000068387A3 (en) Nucleic acids and proteins with interferon-beta activity
AU4567499A (en) Novel mtbx protein and nucleic acid molecules and uses therefor
ZA200110161B (en) Anti-avB3 recombinant human antibodies, nucleic acids encoding same and methods of use.
AU6402694A (en) Methods and materials relating to the functional domains of dna binding proteins
AU3510200A (en) Human dickkopf-related protein and nucleic acid molecules and uses therefor
AU2002219960A1 (en) Molecules of the card-related protein family and uses thereof
AU5894900A (en) Novel molecules of the card-related protein family and uses thereof
AU9222698A (en) Novel molecules of the tnfr-ligand-related protein family and uses thereof
WO2000053776A3 (en) Human kallikrein-like genes
WO2000069901A3 (en) Proteins with insulin-like activity useful in the treatment of diabetes
AU3354499A (en) Human mekk proteins, corresponding nucleic acid molecules, and uses therefor
ZA9710163B (en) Novel carboxylesterase nucleic acid molecules, proteins and uses thereof.
EP0749312A4 (en) -i(DIROFILARIA IMMITIS) Gp29 PROTEINS, NUCLEIC ACID MOLECULES AND USES THEREOF
AU5245900A (en) Novel protein and dna thereof
AU3241895A (en) Apoptosis related protein bcl-y, and methods of use thereof
IL138216A0 (en) Novel fdrg protein and nucleic acid molecules and uses therefor
WO2002004521A3 (en) Proteins with integrin-like activity
WO2000068384A3 (en) NOVEL NUCLEIC ACIDS AND PROTEINS WITH p53 ACTIVITY AND ALTERED TETRAMERIZATION DOMAINS
AU3238200A (en) Purification of liquid protein hydrolysate and the resultant products
AU5772299A (en) Novel molecules of the tango-93-related protein family and uses thereof
AU7846000A (en) Novel human lipase proteins, nucleic acids encoding them, and uses of both of these
AU1855001A (en) A new member of the pak protein family, nucleic acids and methods related to thesame
AU2001294786A1 (en) Use of il-8 protein modulators in the treatment of viral infections
AU7478098A (en) Methods of treatment using nbs-1, antibodies and proteins thereto, and uses of the antibodies
AU4545299A (en) Novel molecules of the aip-related protein family and uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2372881

Country of ref document: CA

Ref country code: CA

Ref document number: 2372881

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 616350

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 48492/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2000930723

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000930723

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000930723

Country of ref document: EP